On February 17, 2022 Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, reported its fourth quarter 2021 results (Press release, Targovax, FEB 17, 2022, View Source [SID1234608204]). Targovax’s CEO will give an online presentation and update on the clinical program to investors, analysts and the press at 10:00 CET today (details below).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
2021 HIGHLIGHTS
ONCOS-102
Reported class-leading ORR of 35% for ONCOS-102 in PD1-refractory melanoma, associated with broad and powerful immune activation in responding tumors
Reported 25.0 months median Overall Survival (mOS) for ONCOS-102 combined with chemotherapy in first line mesothelioma
Granted two Fast-Track designations for ONCOS-102 by the US FDA, for both PD1-refractory melanoma and malignant pleural mesothelioma
NextGen circRNA ONCOS vectors
Expanded the pipeline programs into circular RNA delivery
Appointed Dr. Erik Digman Wiklund as CEO, previous Targovax CBO and CFO and circRNA co-discoverer
Appointed circRNA co-discoverer Dr. Thomas B Hansen as VP of Research to lead the NextGen circRNA ONCOS pipeline program
Announced a research collaboration with Prof. Michael Uhlin at Karolinska Institutet in Stockholm for development and characterization of NextGen ONCOS viruses
Mutant KRAS
Awarded two prestigious research grants towards the TG mut KRAS vaccine program totaling NOK 18m over four years; NOK 9.8m from the Research Council of Norway and NOK 8.2m from Innovation Norway
Corporate
Completed a rights issue raising gross proceeds of NOK 175m
Erik Digman Wiklund, CEO commented: "During 2021, adenoviruses clearly pulled ahead as the most promising class for oncolytic immunotherapy, as demonstrated by convincing clinical data from both Targovax (ONCOS-102) and several of our peers. When it comes to the breadth, depth, and consistency of the translational analyses from our phase 1/2 clinical program, the totality of the ONCOS-102 data package is second to none. As such, Targovax can now soundly be considered one of the front-runners in the oncolytic virotherapy space. We are planning to leverage this position by building an innovative pipeline of NextGen ONCOS viruses, including a move into the emerging circular RNA field."